|
Role of Toxins in Lung Infections Caused by Pseudomonas Aeruginosa Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment by using a genuine medical doctor. We aren't mDs. Always confer with your doctor on Role of Toxins in Lung Infections Caused by Pseudomonas Aeruginosa conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. Role of Toxins in Lung Infections Caused by Pseudomonas Aeruginosa Clinical research trials and Role of Toxins in Lung Infections Caused by Pseudomonas Aeruginosa healthcare trials occur in a lot of of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new does drugs. The role of the studies / undertakings is to solve specific human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to find treatments for all kinds of conditions, including Role of Toxins in Lung Infections Caused by Pseudomonas Aeruginosa. Role of Toxins in Lung Infections Caused by Pseudomonas Aeruginosa Clinical Trials and other clinical trials allow for volunteers to access health treatment choices before they are available to the general public. Many times the test subjects get treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a Role of Toxins in Lung Infections Caused by Pseudomonas Aeruginosa clinical trial. Test subjects typically receive the most effective healthcare possible for their Role of Toxins in Lung Infections Caused by Pseudomonas Aeruginosa condition. Risks are a reality, nonetheless, and could include extra or frequent dr. calls, health hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "R" Clinical Trials Conditions > Role of Toxins in Lung Infections Caused by Pseudomonas Aeruginosa  Role of Toxins in Lung Infections Caused by Pseudomonas Aeruginosa
Role of Toxins in Lung Infections Caused by Pseudomonas Aeruginosa
For Condition: Pseudomonas Infection,Cystic Fibrosis
Status: Recruiting
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: Some bacteria that cause disease can produce toxic substances that may worsen the disease. Pseudomonas aeruginosa is a bacteria that can produce a variety of toxins and is of special interest for patients with cystic fibrosis and repeated long term lung infections. The goal of this study is to determine whether specific toxins produced by Pseudomonas aeruginosa may be important in the disease process of chronic lung infections of patients with cystic fibrosis. This study will attempt to measure bacterial production of toxins in blood and sputum and immune system response to toxins in the blood. Researchers plan to study 4 effector proteins (toxins). 1. exotoxin A 2. Exo S 3. Exo U 4. Pcr V
Details: The goal of this study is to determine whether virulence determinants that use the type III secretory pathway may be important in the pathogenesis of chronic Pseudomonas aeruginosa lung infections in patients with cystic fibrosis (CF). The studies will quantify bacterial effector proteins in serum and sputum and the immune response to specific products as reflected by antibodies in serum. Candidate effector proteins include: (1) exotoxin A, a non-type III-dependent ADP-ribosyltransferase and cytotoxin that does not use the Type III secretory pathway, (2) ExoS, a type III pathway-dependent extracellular ADP-ribosyltransferase with cytotoxic activity, (3) ExoU, another type III-dependent cytotoxin, that is responsible for epithelial injury in acute lung infections, and (4) PcrV, a homolog to the V antigen of Yersinia.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA Patients with cystic fibrosis with a defined mutation in the cystic fibrosis transmembrane regulator (CFTR) (e.g., any of the known variants of the CFTR gene, such as the delta F508 allele). Patients will have been tested or will be tested for the CFTR gene under another protocol. Research volunteers that are age-and race-matched as control subjects. EXCLUSION CRITERIA Patients who are less than 9 years of age. Research volunteers less than 18 years of age. Patients or research volunteers who test positive for human immunodeficiency virus (HIV) or a positive serum test for hepatitis B and/or C virus. Patients or research volunteers who test positive for tuberculosis. Research volunteers with pulmonary disease or infection.
Total Enrollment: 225
Location and Contact Information:
National Heart, Lung and Blood Institute (NHLBI) *Recruiting*
Bethesda, Maryland, 20892
United States
Recruiting Patient and Public Liaison Office 1-800-411-1222
Additional Information:
Study ID Numbers: 980062; 98-H-0062
Study Start Date: February 4, 1998
Record last reviewed: January 9, 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00027183
Other Pseudomonas Infection Studies:
1. Role of Toxins in Lung Infections Caused by Pseudomonas Aeruginosa
Related Studies:
Other Pseudomonas Infection Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Role of Toxins in Lung Infections Caused by Pseudomonas Aeruginosa
|
|
|
|
|
|
|
|
